Acotiamide - Zeria/Astellas Pharma

Drug Profile

Acotiamide - Zeria/Astellas Pharma

Alternative Names: Acofide; Acotiamide hydrochloride hydrate; YM 443; Z-338

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zeria
  • Developer Astellas Pharma; Zeria
  • Class Benzamides; Gastrokinetics; Small molecules; Thiazoles
  • Mechanism of Action Acetylcholine stimulants; Acetylcholinesterase inhibitors; Muscarinic M1 receptor antagonists; Muscarinic M2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-ulcer dyspepsia
  • Phase II Helicobacter infections

Most Recent Events

  • 22 Feb 2018 Astellas Pharma and Zeria Pharmaceutical completes a phase II trial for Non-ulcer dyspepsia and Helicobacter infections in Japan (UMIN000023886)
  • 01 Apr 2017 Zeria Pharmaceutical completes a phase III trial in Non-ulcer dyspepsia in Belgium, Bulgaria, Latvia, Lithuania, Romania, Russia, Slovakia, Sweden, Ukraine, United Kingdom (NCT01973790)
  • 13 Feb 2017 Acotiamide is still in phase-II development for Non-ulcer dyspepsia in USA (PO) (Zeria pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top